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Abstract
Background Gastroesophageal reﬂux disease (GERD) is
a chronic symptomatic condition and may be associated
with erosive esophagitis (EE). Considerable data on the
long-term maintenance of healing of EE are available, but
data on long-term GERD symptom prevention and patient
quality of life (QOL) are limited.
Aims To investigate QOL in subjects with healed EE who
received 12 months of double-blind maintenance treatment
with lansoprazole or ranitidine, followed by long-term
open-label lansoprazole therapy to prevent recurrence of
EE.
Methods Subjects with healed EE received 12 months of
double-blind maintenance treatment with lansoprazole
15 mg once daily or ranitidine 150 mg twice daily,
followed by dose-titrated, open-label lansoprazole therapy
for up to 82 months.
Results During double-blind treatment (n = 206),
lansoprazole-treated patients showed signiﬁcantly (P B
0.05) greater improvements than ranitidine-treated patients
in the frequency, severity, and ‘bothersomeness’ of heart-
burn, the symptom index, problems of activity limitation,
eating and drinking problems, symptom problems, health
distress, and social functioning. During dose-titrated, open-
label treatment (n = 195), all disease-speciﬁc QOL scales
except sleep improved signiﬁcantly (P\0.001) from open-
label baseline at each time-point.
Conclusions Maintenance treatment with lansoprazole
for 12 months in healed EE subjects produced signiﬁcantly
greater improvements in QOL indicators than ranitidine.
These improvements were sustained during dose-titrated,
open-label lansoprazole treatment.
Keywords Quality of life  Lansoprazole 
Erosive esophagitis  Gastroesophageal reﬂux disease 
Long-term maintenance therapy
Introduction
Gastroesophageal reﬂux disease (GERD) is a chronic
symptomatic condition deﬁned as symptoms or mucosal
damage produced by the abnormal reﬂux of gastric con-
tents into the esophagus. Long-term treatment to maintain
healing and symptom relief is often necessary to prevent
erosive esophagitis (EE) and other complications [1].
Recent treatment guidelines for GERD support symptom-
driven therapy [2], although endoscopic studies suggest
that, in most patients, EE will relapse when proton pump
inhibitor (PPI) therapy is stopped [3].
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being measured to assess the overall value of chronic
therapies. The extent of impairment of HRQOL in patients
with GERD has been evaluated using generic HRQOL
questionnaires, GERD-speciﬁc quality of life (QOL)
questionnaires, or a combination of the two types of
instruments [1]. Such evaluations have found that the
impact of GERD on HRQOL in affected individuals is
proportional to the frequency and severity of heartburn, and
is greater than that associated with many other chronic
diseases [1]. QOL has become an important medical end-
point in clinical research [4], reﬂecting increasing aware-
ness that traditional physiological endpoints often fail to
correlate well with patients’ functional status, general well-
being, and satisfaction with therapy. Despite this, patient
QOL data remain limited from studies of long-term GERD
therapy, including treatment with histamine-2 receptor
antagonists (H2RAs) and PPIs. In particular, no QOL data
have yet been published on the treatment of GERD with
PPIs for greater than 12 months’ duration.
The present study investigated QOL in subjects receiv-
ing randomized, double-blind maintenance treatment with
lansoprazole or ranitidine for 12 months, followed by long-
term (up to 82 months), open-label, symptom-based, dose-
titrated lansoprazole therapy for the prevention of EE
recurrence.
Methods
Study Design
The M94-140 study (sponsored by Takeda Global Research
& Development Center, Inc., Deerﬁeld, IL, [TAP Phar-
maceutical Products Inc. is now a part of Takeda Global
Research & Development Center, Inc.]) was a randomized,
parallel-group, multicenter clinical trial conducted in
patients with EE. The trial consisted of an 8-week open-
label lansoprazole acute healing period, a double-blind
treatment period (lansoprazole vs. ranitidine for the main-
tenance of healing) of up to 12 months [5], and a titrated
open-label maintenance treatment period of up to
82 months with lansoprazole (Fig. 1). This report describes
QOL data from the randomized, double-blind maintenance
phase of the study and the titrated open-label maintenance
phase that began when the subject had a recurrence of EE
or completed the double-blind treatment period, whichever
occurred ﬁrst [6].
Inclusion/Exclusion Criteria
Male or female subjects who were at least 18 years of age
with endoscopically proven EE (CGrade 2 according to a
modiﬁed Hetzel-Dent grading scale developed by a com-
mittee of consultant gastroenterologists, and deﬁned as one
or more erosions/ulcerations involving\10 to[50% of the
distal 5 cm of the esophagus [3]) without coexisting duo-
denal ulcer and/or gastric ulcer C3 mm in diameter were
eligible for participation in the acute healing period of this
study. Subjects who had esophagitis due to a coexisting
systemic disease (e.g., scleroderma, viral or fungal infec-
tion) or radiation, caustic or physiochemical trauma were
not eligible to enter the study. To qualify for the double-
blind maintenance phase, subjects were to have endo-
scopically proven healed EE (Grade 0 or 1) at the end of
the 8-week acute healing period, regardless of their
symptom status. Thus, symptomatic subjects could be eli-
gible for the double-blind maintenance phase. Subjects
who completed the double-blind treatment period without
relapse and those who experienced a recurrence of EE
during double-blind treatment were eligible for inclusion in
the titrated open-label treatment period.
Subjects were excluded if they required more than
occasional use (occasional use deﬁned as B10 days per
month) of non-steroidal anti-inﬂammatory drugs, including
cyclooxygenase-2 inhibitors, during the study. However,
aspirin B325 mg/day for cardiovascular indications was
acceptable. In addition, aluminum/magnesium hydroxide
(Gelusil
) use was permitted for the relief of symptoms.
All changes in concomitant medication (increased/
decreased dose or additional drugs) were recorded
throughout the study. The use of anticoagulants, anti-ulcer/
Lansoprazole 30 mg QD
241 patients
Lansoprazole 15 mg QD
100 patients
Ranitidine 150 mg BID
106 patients
Lansoprazole titrated dose
195 patients
Up to 82 months  duration Up to 12 months  duration 8 weeks  duration
Acute treatment period Randomised double-blind period Titrated open-label period
Fig. 1 Study design
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123anti-reﬂux agents, or anticholinergics was not allowed. In
addition, subjects were excluded if they required more than
occasional use (occasional use deﬁned as B10 days per
month) of corticosteroids equivalent to more than 10 mg/
day of prednisone. Full details of inclusion/exclusion cri-
teria for entry into the initial acute treatment period have
been previously described [5].
Dosing and Duration of Treatment
Subjects qualifying for the double-blind maintenance phase
were randomized in an equal ratio to oral lansoprazole
15 mg once daily or oral ranitidine 150 mg twice daily, for
up to 12 months. These doses are currently approved by the
Food and Drug Administration (FDA) for the maintenance
of healing of EE. For the open-label maintenance phase,
healed subjects began treatment with lansoprazole 15 mg
once daily, while subjects who entered this phase unhealed
received lansoprazole 30 mg once daily until healing was
documented. Once endoscopically documented healing had
occurred, the dose of lansoprazole was reduced to 15 mg
once daily. During the remainder of the titrated open-label
treatment period, the dose of lansoprazole was titrated as
required (based on the recurrence of EE and/or symptom-
atic recurrence), with subjects receiving the minimum dose
required to control their gastroesophageal reﬂux (ranging
from a minimum dose of 15 mg/day up to a maximum dose
of 120 mg/day) for up to 82 months.
Efﬁcacy Measurement
Efﬁcacy parameters were measured throughout the two
maintenance phases (double-blind and titrated, open-label
treatment) of the study. Protocol-required visits took place
at months 1, 3, 6, 9, and 12 during the double-blind
maintenance phase and every 12 months during the open-
label maintenance phase. Endoscopic examinations were
undertaken at each scheduled visit (or if the subject was
symptomatic) to document the presence or absence of EE,
thus allowing the recurrence of EE (primary clinical end-
point) to be monitored. For subjects with recurrence of EE
at double-blind or open-label baseline, an evaluation of
healing visit, including endoscopy, took place 8 weeks
after the initiation of healing treatment (lansoprazole
30 mg/day) and after any subsequent periods of healing
treatment until healing was achieved. An unscheduled visit
was also deemed to have taken place when a subject pre-
sented at the clinic for any reason at a time other than that
regularly scheduled. At each visit, symptoms were also
assessed through investigator interview, as were the num-
ber of Gelusil
 tablets taken since the previous visit and
subject QOL (see below).
QOL Assessment
QOL questionnaires were completed during both the
double-blind and open-label study phases to evaluate the
effect of disease status on subjects’ physical, psychologi-
cal, and social function. The questionnaires were devel-
oped using validated scales wherever possible, as described
below. The questionnaires were self-administered by sub-
jects at each protocol-required visit (see above) before all
other visit procedures. QOL assessment was performed by
evaluating the mean changes from baseline to subsequent
visits for each item and/or scale score during each phase of
the study.
General QOL scales used included scales from the
RAND Corporation Medical Outcomes Study (MOS)
questionnaire [7], the 36-item short form (SF-36) [8–10],
and the General Well-Being Schedule [11]. All question-
naire items related to patient experience during the 4-week
period prior to each scheduled visit, except for the general
health perception scale of the SF-36 [8–10]; no time frame
was speciﬁed for this scale. Where no validated scale was
available, disease-speciﬁc scales were developed de novo
by the Technology Assessment Group (San Francisco, CA)
for Takeda Global Research and Development Center, Inc.
A summary of the questionnaire scales is shown in
Appendix 1.
Safety
The safety of lansoprazole was monitored through the
assessment of adverse events, concurrent medication, and
vital signs [6].
Statistical Analyses for QOL Measurements
All subjects who received at least one dose of lansoprazole
or ranitidine during the double-blind maintenance phase of
the study and at least one dose of lansoprazole during the
titrated open-label maintenance phase were included in the
QOL analyses for the respective period.
The QOL outcomes were the reported values for the
parameters shown in Table 1. Whenever necessary, item
scoring was reversed so that a higher score represented
better health or a more positive outcome. Scale scores were
calculated as the mean of the non-missing items compris-
ing the scale. For scales consisting of only two items, a
scale score was computed for a subject only if scores were
present for both items. For scales consisting of more than
two items, a scale score was computed for a subject only if
scores were present for at least half of the items. All scores
were transformed to a 0 to 100-point scale to facilitate
comparison of results among scales (higher numbers indi-
cating improvement/better outcome). The formula for
Dig Dis Sci (2010) 55:1325–1336 1327
123transformation differed for each scale, depending on the
range of possible values, and was determined during the
validation process.
The results are presented as baseline mean (±SD) and
mean change (±SD) at each visit for each QOL item/scale
score. For each study period, the baseline was the last
available value on or before the ﬁrst day of the period.
Baseline values for the double-blind maintenance of heal-
ing period for both treatment groups are those reported at
the end of the acute open-label healing phase prior to
randomization, while baseline values for the open-label
titration period are those reported after double-blind
treatment with ranitidine or lansoprazole.
Changes from double-blind baseline in the mean item
and scale scores at each scheduled visit were compared
between lansoprazole and ranitidine using the Cochran-
Mantel-Haenszel test (for single items with ordered scores
and scales with less than three items) or analysis of variance
(ANOVA) (for scales with three or more items). Both
analyses were adjusted for investigative center. Changes
from titrated open-label baseline in the mean item and scale
scores at each scheduled visit were analyzed using a paired
t-test. Missing post-baseline item scores were imputed as
the last observation carried forward (assuming no change
from the previous visit regarding the speciﬁc item).
Ethical Approval and Informed Consent
All subjects were required to understand and sign the
informed consent form prior to screening, and to
understand and cooperate with the study procedures. Prior
to initiating any study procedure, each investigator site was
granted approval by an Institutional Review Board. The
study adhered to the ethical principles stated in the Dec-
laration of Helsinki (1996 revision) and was conducted in
accordance with FDA guidelines, Guidelines for Good
Clinical Practice governing clinical study conduct, and all
applicable local regulations.
Results
Subject Demographics
A total of 206 subjects entered the double-blind mainte-
nance phase of the study. Of these, 100 received lanso-
prazole 15 mg once daily and 106 received ranitidine
150 mg twice daily for up to 12 months or until recurrence
of EE (Grade C 2). The demographic data for these sub-
jects are summarized by treatment in Table 2. Overall, they
had a mean age of 50.0 years (range: 19–82), and were
mostly male (67%, 139/206) and white (90.0%, 185/206).
Helicobacter pylori status at study enrollment was positive
for 18% of subjects.
Most subjects (95%, 195/206) completed the double-
blind treatment period (experienced recurrence or com-
pleted 12 months of therapy) and entered the dose-titrated
open-label maintenance phase in accordance with the study
criteria. The demographic summary data for these subjects
were very similar to those for the 206 initial double-blind
period enrollees: subjects were mostly male (67%, 131/
195) and white (90%, 176/195), with a mean age of
50.8 years (range: 20–82). Based on histological evaluation
of gastric biopsies, 21% (40/195) of subjects were positive
for H. pylori just prior to open-label treatment, and
approximately half (52%, 102/195) were experiencing
recurrence of EE upon entry into the open-label period; of
those subjects, 70 had received ranitidine and 32 had
received lansoprazole during the double-blind maintenance
phase [5].
During the titrated open-label treatment period, 105 of
the 195 subjects withdrew from the trial. Reasons for
premature discontinuation included adverse events (18
subjects, 9%), personal issues (13 subjects, 7%), poor
compliance (nine subjects, 5%), treatment with another
drug that would interfere with the evaluation of the study
drug (seven subjects, 4%), pregnancy (two subjects, 1%),
therapeutic failure (one subject, 0.5%), and closure of the
study site or the subject was lost to follow-up (55 subjects,
28%).
All analyses were performed using all subjects with
available data (intent-to-treat population). Although some
subjects were treated for up to 82 months during the
Table 1 Primary quality of life outcomes
Scale scores (comprised of multiple items) Item scores
General health perception Comparative health
General well-being Health distress
Energy and vitality Frequency of heartburn
symptoms
Mental health Severity of heartburn
pain
Sleep Comparative heartburn
bothersomeness
Social functioning Degree of heartburn
bothersomeness
Activity limitation problems Problems with taking
care of heartburn
Eating and drinking problems Problems with living
normal life
Symptom problems
Satisfaction with treatment
Indices
Symptom index (symptom
frequency 9 symptom bothersomeness)
1328 Dig Dis Sci (2010) 55:1325–1336
123titrated open-label lansoprazole period, QOL data sum-
marized by time period are presented up to 72 months due
to the paucity of data after this time.
Lansoprazole Dosing
During the double-blind maintenance phase, the mean
duration (±SD) of dosing was 237 ± 143 days (range:
25.0–387.0) for lansoprazole and 89 ± 111 days (range:
3.0–373.0) for ranitidine. This difference was statistically
signiﬁcant (P\0.05). During the titrated open-label
treatment period, the mean duration of lansoprazole dosing
was 56 ± 24 months (range:\1–82 months). The majority
of subjects (62%, 120/195) received titrated open-label
maintenance treatment for at least 5 years ([60 months). A
summary of the duration of lansoprazole exposure for all
subjects during the titrated open-label treatment period is
shown in Table 3.
Treatment Efﬁcacy and Safety
As previously reported for the double-blind maintenance
period of the study, 67% of lansoprazole-treated patients
remained healed of EE at the end of the 12-month period
compared with only 13% of ranitidine-treated subjects [5].
By the end of the titrated open-label treatment period, the
majority of subjects (75%) also remained healed. Most
subjects assessed during the titrated open-label treatment
period had no symptoms or only mild symptoms of day-
time heartburn (95%, 175/185) and night-time heartburn
(94%, 174/185) at their ﬁnal visit. Overall, lansoprazole
was well tolerated during both maintenance phases of the
study, with no unexpected adverse events or laboratory or
biopsy ﬁndings.
QOL
The mean QOL scores were comparable between treatment
groups at the double-blind maintenance period baseline.
During this phase of the study, compared to the ranitidine
group, the lansoprazole group showed a consistent (months
3 through 12) signiﬁcantly (P B 0.05) greater improve-
ment in the symptom pain-related QOL scales measuring
heartburn severity and frequency (Table 4; Fig. 2), in the
heartburn bothersomeness scales, and in other symptom-
speciﬁc scales (symptom index scale and symptom prob-
lem scale). Consistent with symptom improvement, scales
reﬂecting more general symptom-related QOL aspects
(eating and drinking problems, social functioning, and the
health distress scale) also showed signiﬁcantly (P B 0.05)
greater improvements in the lansoprazole group compared
to the ranitidine group during months 3 through 12
(Table 4). For other more global scales (the comparative
health and general health scales), signiﬁcantly (P B 0.05)
greater improvements in scores with lansoprazole com-
pared to ranitidine were found at some visits (Table 5). In
addition, lansoprazole-treated patients were signiﬁcantly
more satisﬁed with treatment than ranitidine-treated
patients (months 3, 9, and 12).
Baseline QOL scores and mean changes from baseline at
12-month intervals during the titrated open-label treatment
period are summarized in Tables 6 and 7. Of the global
Table 2 Subject demographics at double-blind maintenance baseline
Lansoprazole 15 mg
once daily
(n = 100)
Ranitidine 150 mg
twice daily
(n = 106)
Gender, n (%)
Male 72 (72) 67 (63)
Race, n (%)
White 91 (91) 94 (89)
Black 7 (7) 7 (7)
Other 2 (2) 5 (5)
Age, years
a
Mean (SD) 49.6 (13.4) 50.3 (14.3)
Range 19–77 19–82
Erosive esophagitis grade, n (%)
a
Grade 2 58 (58) 63 (59)
Grade 3 36 (36) 32 (30)
Grade 4 6 (6) 11 (10)
H. pylori status, n (%)
b N = 99 N = 105
Negative 82 (83) 86 (82)
Weight (males), pounds
a
Mean (±SD) 193.1 (33.8) 203.7 (31.7)
Minimum–maximum 130–310 134–273
Weight (females), pounds
a
Mean (±SD) 172.6 (29.5) 176.2 (33.2)
Minimum–maximum 125–246 97–237
Body mass index
Mean (±SD) 28.5 (4.5) 29.5 (4.8)
Minimum–maximum 20–47 17–41
Alcohol use, n (%)
Current drinker 52 (52) 52 (49)
Non-drinker
c 48 (48) 54 (51)
Current tobacco use, n (%)
Tobacco user 28 (28) 22 (21)
Tobacco non-user
d 72 (72) 84 (79)
SD standard deviation
a At acute baseline. Baseline weight is missing for one male subject
in the ranitidine group
b Assessed by histology (Warthin-Starry silver stain) at acute base-
line; the results were not available for two patients
c Includes ex-drinkers
d Includes ex-tobacco users
Dig Dis Sci (2010) 55:1325–1336 1329
123health scales, general health perception, comparative
health, and health distress consistently demonstrated sta-
tistically signiﬁcant improvements from baseline at
12 months, which were sustained during 72 months of
follow-up (Table 6). In addition, a signiﬁcant improvement
compared to baseline was reported in ‘Energy and vitality’
at 12 months and in ‘General well-being’ at 48 months. All
GERD-speciﬁc scales (social functioning, heartburn pain
frequency, heartburn pain severity, comparative heartburn
bothersomeness, degree of heartburn bothersomeness,
symptom index, activity limitation, eating and drinking
problems, symptom problems, taking care of heartburn
problems, living normal life problems, and satisfaction
with treatment) except sleep improved signiﬁcantly
(P\0.001) at 12 months from titrated open-label baseline.
The improvements were sustained throughout the 72-
month follow-up period (Table 7). The improvement in
severity and frequency of heartburn observed during the
double-blind maintenance period was also sustained
throughout the 72-month period of open-label follow-up.
Discussion
The increasing interest in measuring subjects’ QOL as an
outcome reﬂects increasing awareness that traditional
physiological endpoints often do not correlate well with
patients’ functional status, general well-being, and satis-
faction with therapy. Improved QOL during the short-term
treatment of GERD has been reported with ranitidine
[12–14] and with PPIs [15–19]. Bytzer et al. [17] demon-
strated that GERD patients treated with rabeprazole 20 mg
or omeprazole 20 mg for 7 days showed improvement in
QOL parameters with no signiﬁcant differences between
the two PPIs. Similarly, 4 weeks of treatment of GERD
with esomeprazole 40 mg produced signiﬁcant and clini-
cally meaningful improvements in QOL that were main-
tained during 6 months of maintenance therapy with
esomeprazole [18]. However, few studies have assessed
longer term GERD symptom prevention and QOL data in
subjects receiving long-term PPIs.
The present study demonstrates that maintenance treat-
ment with lansoprazole for 12 months is signiﬁcantly bet-
ter than maintenance treatment with ranitidine in
improving subjects’ QOL. Another study has also shown
greater improvement in QOL with PPIs than with H2RAs
during up to 6 months of maintenance treatment [20].
However, one study found no difference between PPIs and
H2RAs in terms of the improvement in QOL during
maintenance therapy [21]. All of these studies, however,
showed that continued treatment of GERD is associated
with improved QOL.
The results of the present study also show that long-
term, dose-titrated, open-label use of lansoprazole in sub-
jects with healed EE provides a continued and sustained
improvement in physical, psychological, and social func-
tioning (QOL measures). Such improvements in QOL are
consistent with the decrease in severity and frequency of
heartburn pain reported during the open-label period of this
study and lend support to the efﬁcacy data from this phase
of the trial, which show that long-term continuous lan-
soprazole therapy is effective in maintaining remission of
EE for up to 72 months, with relatively few subjects
experiencing recurrence during this period [6]. In addition,
the results of the current study show that, if symptoms
develop (that could adversely affect QOL), symptom-based
dose adjustment of lansoprazole is effective in controlling
these symptoms [6].
In the present study, sleep improved during double-blind
maintenance therapy with lansoprazole. The greatest
Table 3 Duration and extent of lansoprazole exposure for all subjects during the titrated open-label period
Duration (months) All subjects
(n = 195)
n (%)
By daily dose of lansoprazole
a
B15 mg
n
[15–30 mg
n
[30–60 mg
n
[60–90 mg
n
[90–120 mg
n
B12 16 (8.2) 62 78 37 5 5
[12–24 15 (7.7) 21 20 7 1 0
[24–36 13 (6.7) 16 17 6 0 1
[36–48 10 (5.1) 14 15 4 0 0
[48–60 21 (10.8) 17 13 6 1 0
[60–72 57 (29.2) 25 19 2 0 0
Mean ± SD 56.1 ± 24.13 – – – – –
Range \1–82.4
SD standard deviation
a Subjects may have increased and/or decreased their dose during the study. Such subjects are counted once at each dose level administered;
hence, the sum of subjects across doses is different from the total number of subjects enrolled in the titrated open-label treatment period
1330 Dig Dis Sci (2010) 55:1325–1336
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123improvement was observed after 3 months of treatment,
and, thereafter, leveled off slightly. The improvement with
lansoprazole was signiﬁcantly greater than that with rani-
tidine after 3 and 6 months of treatment. The improvement
in sleep during the double-blind maintenance phase was
maintained during titrated open-label treatment with lan-
soprazole. Studies have shown that short-term (4–8 weeks)
treatment with a PPI improves sleep in patients with GERD
[15, 18, 20, 22]. In these studies, the beneﬁcial effect of PPI
therapy on sleep leveled off after 2–4 weeks and then
remained constant [18, 20, 22], even during 6 months of
maintenance therapy [18, 20]. However, the results of the
present study suggest that sleep improves during the early
months of maintenance treatment with lansoprazole, and
that this improvement is maintained during long-term
treatment. Improvements in sleep have been shown to
correlate with a reduction in the frequency and severity of
heartburn episodes [15]. As GERD and its associated
symptoms have a signiﬁcant impact on subjects’ QOL,
successful therapeutic intervention is expected to be asso-
ciated with a clinically signiﬁcant improvement in HRQOL
[1, 4, 23]. Indeed, the present data support previous studies
in which acid suppression therapy improves HRQOL [22,
23]. For example, Mathias et al. [22] demonstrated that
lansoprazole 15 mg daily, lansoprazole 30 mg daily, or
omeprazole 20 mg daily for 8 weeks signiﬁcantly
improved most HRQOL scales compared with placebo in a
large group of patients with acute EE. The improvements
in QOL leveled off after 2 weeks and were maintained in
all of the study groups.
In the present study, improvements in QOL were
observed after only 1 month of double-blind maintenance
Table 5 Changes in global health scores during the double-blind maintenance period
Scale Month of visit
Mean change from baseline
a
Double-blind baseline
b 13 6 9 1 2
L R LR LR LR L R LR
General health perception 57.5 56.9 -0.4
c -5.4 -0.4 -4.3 -1.7 -4.3 -1.2 -4.8 -3.0 -4.4
Comparative health 54.7 53.6 ?15.2 ?18.4 ?7.0
c -2.3 ?2.1 -2.8 ?0.5 -2.8 -1.0 -3.6
Health distress 43.4 47.6 ?15.5 ?15.1 ?20.2
d ?8.0 ?18.3
c ?9.2 ?17.3 ?10.4 ?19.9
c ?8.8
General well-being 67.6 68.9 -0.9 -5.6 -1.0 -4.8 -1.4 -4.3 -0.8 -4.8 -1.2 -5.4
Energy and vitality 45.5 45.0 ?0.6 -2.9 ?1.3 -1.4 -0.8 -1.9 0 -2.8 -1.3 -3.5
Mental health 62.1 63.4 ?2.4 ?1.7 ?4.3 ?2.2 ?3.8 ?2.2 ?4.9 ?2.5 ?5.0 ?2.0
L lansoprazole, R ranitidine
a A positive score change indicates improvement
b Last value obtained at or prior to the start of the double-blind maintenance period
c P B 0.05 versus ranitidine
d P B 0.01 versus ranitidine
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Fig. 2 Change in severity and
frequency of heartburn during
the double-blind maintenance
period. A positive change
indicates improvement
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123treatment with lansoprazole. These improvements tended
to peak after 3 months of treatment and, thereafter, were
maintained during 12 months of double-blind treatment.
By contrast, the improvements in QOL with ranitidine
appeared to peak after 1 month (at which point they were
similar in magnitude to the improvements with lansopraz-
ole) and then tended to drop off to a level lower than that
observed at 1 month and signiﬁcantly lower than that
observed with lansoprazole at the same time point. The
improvements in QOL with lansoprazole during the dou-
ble-blind maintenance phase were sustained during symp-
tom-based, dose-titrated, open-label therapy for up to
72 months.
The long-term effects of other PPIs on HRQOL have
been investigated in subjects with GERD, although studies
are limited to 12 months’ treatment duration. In one study,
Table 7 Changes in disease-speciﬁc scores during the titrated open-label period
Scale Open-label baseline
a Month of visit
Mean change from baseline
b
12 24 36 48 60 72
Heartburn pain-related scales
Severity
c 68.0 ?17.1 ?16.8 ?17.7 ?18.4 ?18.4 ?19.3
Frequency
c 73.0 ?14.8 ?13.8 ?15.2 ?16.1 ?15.6 ?15.6
‘Bothersomeness’ comparative
c 47.9 ?17.8 ?15.9 ?12.6 ?12.9 ?11.4 ?11.0
‘Bothersomeness’ degree
c 64.4 ?19.2 ?19.5 ?19.8 ?21.3 ?19.6 ?20.8
Symptom index
c,d 77.4 ?7.5 ?7.6 ?7.7 ?8.2 ?7.8 ?7.9
Taking care of heartburn problems scale
c 80.1 ?13.1 ?11.4 ?11.9 ?13.1 ?12.2 ?12.3
Related problems scales
Activity limitation
c 79.6 ?9.6 ?9.7 ?9.9 ?10.5 ?9.2 ?10.1
Eating/drinking
c 84.2 ?8.6 ?8.6 ?8.1 ?8.9 ?7.9 ?8.5
Symptom problems
c 84.1 ?9.0 ?8.4 ?8.7 ?9.7 ?8.6 ?9.3
Living normal life
c 84.4 ?7.8 ?7.9 ?8.6 ?9.2 ?8.7 ?9.0
Social function
c 86.7 ?8.3 ?8.7 ?9.1 ?10.0 ?8.7 ?9.6
Sleep 67.7 ?1.7 ?0.4 ?0.9 ?0.2 ?0.3 ?0.4
Treatment satisfaction
c 66.7 ?24.8 ?25.0 ?25.4 ?25.7 ?25.4 ?25.6
a Last value obtained at or prior to the start of the titrated open-label period
b A positive score change indicates improvement
c P B 0.001 for all time points versus baseline
d Symptom index = symptom frequency 9 symptom ‘bothersomeness’
Table 6 Changes in global health scores during the titrated open-label period
Scale Open-label baseline
a Month of visit
Mean change from baseline
b
12 24 36 48 60 72
General health perception 64.2 ?4.2
d ?5.4
e ?4.2
d ?5.1
e ?3.3
c ?3.5
c
Comparative health 48.6 ?7.9
e ?7.4
e ?5.0
d ?3.7
c ?5.8
e ?4.1
c
Health distress 61.7 ?5.1
c ?6.3
d ?6.5
e ?7.2
e ?3.9 ?6.2
d
General well-being 66.3 ?2.4 ?2.7 ?1.8 ?3.6
c ?1.4 ?1.8
Energy and vitality 55.3 ?3.2
c ?1.0 ?2.4 ?1.0 ?0.4 ?2.2
Mental health 73.7 ?0.9 ?0.9 ?1.3 ?1.5 ?1.7 ?0.8
a Last value obtained at or prior to the start of the titrated open-label period
b A positive score change indicates improvement
c P B 0.05 versus baseline
d P B 0.01 versus baseline
e P B 0.001 versus baseline
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123esomeprazole and ranitidine treatment strategies were
compared [20]. Following a 4-week symptom-control
phase (esomeprazole 40 mg once daily), patients were
randomized to 6 months of esomeprazole 20 mg once daily
continuously or on-demand, or ranitidine 150 mg twice
daily continuously. Esomeprazole 40 mg once daily
improved QOL during the symptom-control phase and at 6
months; both esomeprazole regimens were signiﬁcantly
more effective than ranitidine in improving QOL. How-
ever, continuous esomeprazole once daily was better than
esomeprazole on-demand in maintaining QOL, and was
associated with greater patient satisfaction.
Several limitations of the current study should be
highlighted. The ﬁnal phase of the study was open-label in
design, offering no comparison with placebo or active
treatment. In addition, study drug information was not
collected in sufﬁcient detail during the study to allow for a
calculation of compliance. The interpretation of data may
also be affected by various factors, including spontaneous
remission of GERD and subjective interpretation of
symptoms. However, the paucity of relevant literature
prevents any discussion as to whether ‘switching’ to open-
label medication may have had an effect on the symptoms
reported. Regarding QOL assessment, enrollment for this
long-term study began in 1995, whereas validated speciﬁc
QOL instruments only became generally available for use
in GERD studies after 1997. Thus, where no validated
QOL scales were available, disease-speciﬁc scales were
developed de novo by the Technology Assessment Group.
Although such scales might be less accurate than validated
HRQOL questionnaires [24], disease-speciﬁc instruments
are more appropriate and may avoid the sensitivity issues
previously described with some QOL tools, particularly
generic instruments [25]. An additional limitation of the
present study is that the minimum clinically important
difference (MCID) for the HRQOL measures used was not
identiﬁed for the GERD population. Thus, the proportion of
subjects in each treatment group whose scores improved at
least as much as the MCID in the HRQOL measures could
not be calculated.
Some clinicians may not always agree that chronic daily
use of PPIs is an appropriate therapeutic intervention.
However, the lifetime management goals of GERD are to
control esophageal as well as extraesophageal symptoms,
maintain a stable non-inﬂamed esophageal mucosa, and
prevent complications [26]. The current long-term study
has conﬁrmed the clinical efﬁcacy and tolerability of PPI
therapy in individuals with EE [6]. Signiﬁcant improve-
ments in QOL can be achieved in this patient population
with long-term symptom-driven PPI therapy, as described
in the present study, and this is particularly important as the
impact of GERD on HRQOL can be greater than that
associated with many other chronic diseases [1]. Thus,
PPIs, including lansoprazole, represent the mainstay of
treatment in the long-term medical management of GERD.
In summary, maintenance treatment with lansoprazole
for 12 months produced signiﬁcantly greater improvements
in general health and QOL indicators in subjects with EE
than maintenance treatment with ranitidine. These
improvements in QOL were sustained during 72 months of
open-label, dose-titrated, maintenance treatment with lan-
soprazole. Thus, PPI therapy based on symptom-driven
dose titration provides a sustained improvement in QOL
during the long-term treatment of GERD.
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Appendix. 1: Summary of QOL Scales Used
General Scales
General Health Perception
This ﬁve-item scale from the RAND Corporation MOS
questionnaire [7] assesses general health status, with each
item measured on a ﬁve-point scale.
Comparative Health
This single item from the SF-36 of the MOS questionnaire
[8–10] asks how the patient’s health is compared to
4 weeks ago, and is measured on a ﬁve-point scale.
1334 Dig Dis Sci (2010) 55:1325–1336
123Health Distress
This single item assesses the degree of concern/worry with
health on a scale ranging from 0 to 10, and comes from the
18-item General Well-Being Schedule [11].
General Well-Being
This two-item scale, adapted from the General Well-Being
Schedule [11], consists of a life satisfaction item and an
item asking how frequently the patient is bothered by ill-
ness, bodily disorder, pains, or fears about health. Both
items are measured on a ﬁve-point scale.
Energy and Vitality
This ﬁve-item scale from the MOS questionnaire [7]
assesses levels of energy and fatigue. The items are mea-
sured on a six-point scale.
Mental Health
This ﬁve-item scale from the MOS questionnaire [7]
assesses anxiety, depression, and positive affect. The items
are measured on a six-point scale.
Disease-Speciﬁc Scales
These scales and items were developed by TAP.
Sleep
This eight-item scale assesses sleeping problems resulting
from the patient’s heartburn condition. The items are
measured on a six-point scale.
Social Functioning Scale
This two-item scale assesses social functioning problems
resulting from the patient’s heartburn condition. The items
are measured on a ﬁve-point scale.
Heartburn Symptoms—Frequency
This single item asks patients how many days they had
heartburn symptoms in the past 4 weeks. The item is
measured on a six-point scale.
Heartburn Pain—Severity
This single item asks how severe the pain resulting from
the heartburn condition has been during the past 4 weeks,
and is measured on a scale of 0–10.
Comparative Heartburn Bothersomeness
This single item asks if the patient’s heartburn condition is
worse, about the same, or better compared to 4 weeks ago,
and is measured on a ﬁve-point scale.
Degree of Heartburn Bothersomeness
This single item asks patients about the degree of bother-
someness of their heartburn condition and is measured on a
ten-point scale.
Symptom Index
Symptom frequency 9 symptom bothersomeness.
Problems—Activity Limitations
This four-item scale assesses problems with activity limi-
tation resulting from the patient’s heartburn condition. The
items are measured on a ﬁve-point scale.
Problems—Eating and Drinking
This six-item scale assesses problems with eating and
drinking resulting from the patient’s heartburn condition.
The items are measured on a ﬁve-point scale.
Problems—Symptoms
This seven-item scale assesses problems with heartburn
symptoms resulting from the patient’s heartburn condition.
The items are measured on a ﬁve-point scale.
Problems—Taking Care of Heartburn
This single-item scale assesses the problem of taking care
of heartburn resulting from the patient’s heartburn condi-
tion. The item is measured on a ﬁve-point scale.
Problems—Living a Normal Life
This single-item scale assesses the problem of living a
normal life resulting from the patient’s heartburn condition.
The item is measured on a ﬁve-point scale.
Satisfaction with Treatment
Satisfaction items were not asked at screening. Three
questions were asked (satisfaction with relief from heart-
burn symptoms, with the results of the treatment program,
and with the study medication), with each item measured
on a ﬁve-point scale at each evaluation.
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